Since it was first approved by the FDA in 1977, tamoxifen has become one of the most effective and widely prescribed treatments for breast cancer. Millions of women have used it, not only as a treatment for breast cancer, but, in some cases, to prevent it from developing in the first place. And because it is a pill and has few serious side effects, tamoxifen has become a favorite of doctors and patients alike. But for some women that protection is only temporary. Now, results of a study conducted by researchers at Ohio State’s Comprehensive Cancer Center may offer new hope.¹ Analyzing over 300 human tumors, researchers here have identified the pathways that certain cancer cells use to render tamoxifen ineffective.
